Cerebri represents a fundamentally new therapeutic category within the traumatic brain injury treatment map. While existing approaches—surgery, pharmacological interventions, and rehabilitation—focus on stabilizing patients and managing symptoms, Cerebri is designed to directly target the underlying biological damage caused by TBI.

Cerebri’s first-in-class astrocyte-based cell therapies and astrocyte-derived extracellular vesicles (EVs) harness the natural regenerative and neuroprotective functions of astrocytes to promote neural repair, reduce inflammation, and support synaptic recovery. Unlike conventional drugs that modulate isolated pathways, Cerebri’s platform delivers complex, biologically active signals that mirror the brain’s own repair mechanisms.

Within the treatment map, Cerebri occupies a novel position bridging pharmacological intervention and regenerative medicine—introducing a disease-modifying approach aimed at restoring brain function rather than merely compensating for lost function. This positions Cerebri as a transformative therapy capable of altering the long-term trajectory of TBI, with the potential to prevent chronic cognitive impairment and reduce the risk of progressive neurodegeneration.

In contrast to symptomatic treatments such as anti-seizure drugs or rehabilitation therapies, Cerebri’s approach addresses the root causes of injury by enabling true neurological recovery.

Cerebri’s pipeline is built to convert proprietary innovation into clinical-stage assets, with two lead programs progressing toward IND submission and first-in-human trials. This structured development strategy creates clear value inflection points while establishing a platform for expansion into multiple high-value neurological indications.